Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis

Key facts

Sponsor

American College of Radiology Imaging Network

Principal Investigator

Gerald D. Dodd, MD, M.D., Ph.D

The University of Texas Health Science Center at San Antonio

Intervention

radiofrequency ablation(device)

Enrollment

51 enrolled

Eligibility

18-120 years · All sexes

Timeline

2005 – 2010

Study locations (18)

• Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States
• Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
• Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
• University of California Davis Cancer Center, Sacramento, California, United States
• Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
• UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States
• William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States
• Mayo Clinic Cancer Center, Rochester, Minnesota, United States
• Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
• Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
• Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
• Rhode Island Hospital Comprehensive Cancer Center, Providence, Rhode Island, United States
• Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
• +3 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT07441369
  Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
  Fudan University
• RECRUITINGPHASE2NCT07175441
  Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
  Riboscience, LLC.
• RECRUITINGPHASE2NCT07560488
  Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE1, PHASE2NCT07291076
  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
  Bristol-Myers Squibb
• RECRUITINGPHASE2NCT07010497
  A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
  Asan Medical Center
• RECRUITINGPHASE1, PHASE2NCT07500220
  Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
  Beijing Biotech
• RECRUITINGPHASE2NCT07413354
  Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
  Tongji Hospital
• RECRUITINGNANCT07365527
  Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases
  Zealand University Hospital

See all trials for Adult hepatocellular carcinoma →